Risk factors for cytomegalovirus reactivation in autoimmune bullous disease patients on immunosuppressive therapy.

Abstract

1. Hofmann SC, Leandro MJ, Morris SD et al. Effects of rituximabbased B-cell depletion therapy on skin manifestations of lupus erythematosus Report of 17 cases and review of the literature. Lupus 2013; 22: 932–9. 2. Gr€ onhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: A population-based cohort of 1088 patients in Sweden. Br. J. Dermatol. 2011; 164: 1335–41. 3. Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA et al. Assessment of Response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018; 154: 1432–40. 4. McCarthy EM, Sutton E, Nesbit S et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology 2018; 57: 470–9. 5. Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield MEP. Responses to rituximab suggest B cellindependent inflammation in cutaneous systemic lupus erythematosus. 2015; 1–23. https://doi.org/10.1002/art.39085.